Drug Shortage Report for TEVA-BUPROPION XL

Last updated on 2025-01-30 History
Report ID 230958
Drug Identification Number 02439662
Brand name TEVA-BUPROPION XL
Common or Proper name BUPROPION XL 300MG SR TAB
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) BUPROPION HYDROCHLORIDE
Strength(s) 300MG
Dosage form(s) TABLET (EXTENDED-RELEASE)
Route of administration ORAL ORAL
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 90's
ATC code N06AX
ATC description ANTIDEPRESSANTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2024-06-20
Estimated end date 2025-01-20
Actual end date 2025-01-29
Shortage status Resolved
Updated date 2025-01-30
Company comments On Allocation - Covering Key Accounts
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v33 2025-01-30 French Compare
v32 2025-01-30 English Compare
v31 2025-01-23 French Compare
v30 2025-01-23 English Compare
v29 2025-01-16 French Compare
v28 2025-01-16 English Compare
v27 2024-12-19 French Compare
v26 2024-12-19 English Compare
v25 2024-12-13 French Compare
v24 2024-12-13 English Compare
v23 2024-11-14 French Compare
v22 2024-11-14 English Compare
v21 2024-11-01 French Compare
v20 2024-11-01 English Compare
v19 2024-10-24 French Compare
v18 2024-10-24 English Compare
v17 2024-10-11 French Compare
v16 2024-10-11 English Compare
v15 2024-09-12 French Compare
v14 2024-09-12 English Compare

Showing 1 to 20 of 33